The Safety, Tolerability, and Efficacy of IBR900 Cell Injection in Relapsed/Refractory B-cell Non Hodgkin Lymphoma

Abroad (travel likely)RecruitingPHASE1

Conditions

Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
Contact: Study coordinator (Hongyan Tong) · hongyantong@aliyun.com · 8613958122357
Shanghai Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Contact: Study coordinator (Weili Zhao) · zwl_trial@163.com · 8613512112076

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

Refractory Non-Hodgkin Lymphoma · Burkitt Lymphoma · Mantle Cell Lymphoma

Abroad (travel likely)RecruitingPHASE1

San Francisco, United States

A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Abroad (travel likely)RecruitingEARLY_PHASE1

Beijing, China · Beijing, China

A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy

Acute Lymphoblastic Leukemia · Non-hodgkin Lymphoma

Abroad (travel likely)RecruitingEARLY_PHASE1

Hangzhou, China

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

B-cell Lymphoma · Non-Hodgkin Lymphoma · B-cell Malignancy

Abroad (travel likely)RecruitingPHASE1, PHASE2

Westwood, United States · St Louis, United States